العربية

Archive for April, 2018

Cancer Research Accelerates New Therapies

Lin-Hollingsworth-Batra-2018-04-03.jpg
From left to right; Chi Lin, MD, PhD, radiation oncologist, Michael Hollingsworth, PhD, researcher and Surinder Batra, PhD, researcher

One of the differentiators of the Fred & Pamela Buffett Cancer Center is the integration of scientists and clinicians, which allows them to collaborate in the evaluation of our cancer patients to design new treatments.

One example of this bench-to-bedside research coming to fruition can be seen through the collaboration of Chi Lin, MD, PhD, a radiation oncologist and researcher Surinder Batra, PhD, associate director for education and training at the Fred & Pamela Buffett Cancer Center. Through Dr. Batra’s basic science research lab, a pathway was discovered in which cholesterol is converted into other compounds in pancreatic cells that contributes to radiation therapy resistance. Dr. Batra’s lab then found another drug that is effective in inhibiting this cholesterol synthesis pathway, thereby increasing radiosensitivity in tumor cells.

This laboratory discovery is now available to patients through a clinical trial that combines chemotherapy with this drug to sensitize pancreatic tumors to radiation. “This is very important because current protocols for radiation therapy are very limited in their effectiveness on pancreatic tumors,” says Michael Hollingsworth, PhD, associate director for Basic Research at the Fred & Pamela Buffett Cancer Center.

“While pancreatic cancer is still extremely difficult to treat, we are making huge progress in understanding the disease,” says Dr. Hollingsworth.

 

“Our goal is to turn these discoveries into improved diagnostics, new therapies and other ways to improve survival and quality of life for these patients.”

 

To schedule an appointment with a specialist at Nebraska Medicine, call +1-402-559-3090 or OIHS@nebraskamed.com.

 

Nebraska Medicine Receives Nebraska’s Safest Companies Award

The National Safety Council, Nebraska (NSCN) recently awarded Nebraska Medicine with its “Nebraska’s Safest Companies” award. It will be presented on Wednesday, May 9, as part of the NSCN’s 35th annual Celebration of Safety event. NSCN is a private, nonprofit organization that partners with businesses, schools, law enforcement, firefighters, hospitals and Nebraska communities to provide education and training focused on keeping Nebraskans safe.

The award signifies our exemplary safety record, which is better than the national average when compared to the rest of our industry and recognizes comprehensive safety programs that our organization has implemented.

“The Celebration of Safety honors organizations that have achieved excellence in safety this past year and we are proud to recognize their achievements in providing a safer Nebraska for their employees and their families,” says Eric Koeppe, president and CEO, National Safety Council, Nebraska.

“At Nebraska Medicine, we are focused on being the safest place possible — for patients, their families and our employees,” says CEO Dan DeBehnke, MD, MBA. “The recent Shout Out for Safety initiative, in which we address safety concerns on a daily basis, is one example of our commitment to improving safety. The upcoming Zero Harms Tools training for all colleagues is the next step on our journey to safety and high reliability. “

To schedule an appointment with a specialist at Nebraska Medicine, call +1-402-559-3090 or OIHS@nebraskamed.com.

Lung Transplant Program Celebrates Certification

 

Since launching in 2015, the Lung Transplant Program has achieved several milestones. Most recently, it earned certification from the Centers for Medicare and Medicaid Services (CMS).

According to Heather Strah, MD, Lung Transplant medical director, achieving certification was a two-year process during which the program demonstrated that Nebraska Medical Center and UNMC were committed to lung transplant and able to provide good patient outcomes.

“CMS certification means Nebraska Medical Center and UNMC will be able to offer lung transplant to more patients with more types of insurance,” says Dr. Strah. “This is an accomplishment for our program and it demonstrates that our young Lung Transplant Program is able to provide patients with the same quality care that they would find elsewhere, but now much closer to home.”

To date, there have been 24 lung transplants performed at Nebraska Medical Center.

Some members of the Lung Transplant Program gathered to celebrate the program’s recent accomplishment. Pictured are (front row, left to right) Bobbi Heffelfinger, nurse coordinator; Heather Strah, MD, Lung Transplant medical director; Aleem Siddique, MD, Lung Transplant surgical director; Heidi Brink, pharmacist; Bernadette Vacha, transplant coordinator (back row) Austin Thompson, MD, Pulmonary Hypertension medical director; Joseph Sisson, MD, Sleep, Pulmonary, Critical Care and Allergy, division chief and Doug Bremers, Donate Life.

To schedule an appointment with a specialist at Nebraska Medicine, call +1-402-559-3090 or OIHS@nebraskamed.com.

Cancer Research Accelerates New Therapies

Lin-Hollingsworth-Batra-2018-04-03.jpgFrom left to right; Chi Lin, MD, PhD, radiation oncologist, Michael Hollingsworth, PhD, researcher and Surinder Batra, PhD, researcher

One of the differentiators of the Fred & Pamela Buffett Cancer Center is the integration of scientists and clinicians, which allows them to collaborate in the evaluation of our cancer patients to design new treatments.

One example of this bench-to-bedside research coming to fruition can be seen through the collaboration of Chi Lin, MD, PhD, a radiation oncologist and researcher Surinder Batra, PhD, associate director for education and training at the Fred & Pamela Buffett Cancer Center. Through Dr. Batra’s basic science research lab, a pathway was discovered in which cholesterol is converted into other compounds in pancreatic cells that contributes to radiation therapy resistance. Dr. Batra’s lab then found another drug that is effective in inhibiting this cholesterol synthesis pathway, thereby increasing radiosensitivity in tumor cells.

This laboratory discovery is now available to patients through a clinical trial that combines chemotherapy with this drug to sensitize pancreatic tumors to radiation. “This is very important because current protocols for radiation therapy are very limited in their effectiveness on pancreatic tumors,” says Michael Hollingsworth, PhD, associate director for Basic Research at the Fred & Pamela Buffett Cancer Center.

“While pancreatic cancer is still extremely difficult to treat, we are making huge progress in understanding the disease,” says Dr. Hollingsworth.

“Our goal is to turn these discoveries into improved diagnostics, new therapies and other ways to improve survival and quality of life for these patients.”

To schedule an appointment with a specialist at Nebraska Medicine, call +1-402-559-3090 or OIHS@nebraskamed.com.

Loading